News|Videos|November 16, 2026

Haley B. Naik, M.D., M.H.Sc.,on the true prevalence of hidradenititis suppurativa

Hidradenitis suppurativa was long thought to be a rare condition, but global data put the prevalence at 1%, says Naik, co-chair of the new AAD-HS Foundation guidelines for the disease.

The American Academy of Dermatology (AAD) and the Hidradenitis Suppurativa Foundation published their first joint guidelines of care for hidradenitis suppurativa (HS) in late October in the Journal of the American Academy of Dermatology. Haley B. Naik, M.D., M.H.Sc., a professor in the Department of Dermatology at the University of California, San Francisco, and president of the Hidradenitis Suppurativa Foundation, co-chaired the 13-member work group that wrote the guidelines. Editors at Managed Healthcare Executive and Dermatology Times spoke with Naik shortly after the guidelines.

HS causes painful lumps deep in the skin, typically where skin rubs together, such as the armpits, inner thighs and groin. More than 3 million people in the United States have been diagnosed with the condition, according to the AAD news release announcing the guidelines. The last set of guidelines was published in 2019.

For many years after HS was first described, it was considered a rare condition, Naik noted, and the National Institutes of Health labeled it as such. Epidemiologic data starting in the 2010s began to show otherwise. Naik said the rare-disease label contributed to the condition being underrecognized and to limited research and research funding.

More recent work, including a meta-analysis of Global Hidradenitis Suppurativa Atlas studies published in JAMA Dermatology in 2025, puts worldwide prevalence at about 1%. The new guidelines cite a range of 0.67% to 1.46% of the global population.

Naik is careful not to describe HS as a disease on the rise. "We don't have data that supports that the incidence of HS is increasing," she said. Instead, she reads the newer numbers as a correction. "HS has been underrecognized for so long that we're only now beginning to understand its prevalence," Naik said.

That history of underrecognition still shapes care. The guidelines note that diagnostic delays in HS average seven to 10 years, and the AAD news release points out that HS is often mistaken for acne or infection.


Related to this article